{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:07:06Z","timestamp":1790917626222,"version":"4.1.0"},"reference-count":83,"publisher":"Informa UK Limited","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1517\/14656566.6.16.2821","type":"journal-article","created":{"date-parts":[[2005,11,30]],"date-time":"2005-11-30T12:22:53Z","timestamp":1133353373000},"page":"2821-2829","source":"Crossref","is-referenced-by-count":71,"title":["Treatment of visceral leishmaniasis"],"prefix":"10.1517","volume":"6","author":[{"given":"Shyam","family":"Sundar","sequence":"first","affiliation":[{"name":"Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 221005, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 221005, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2005,11,30]]},"reference":[{"key":"e_1_2_1_3_1","unstructured":"WHO: The leishmaniases and leishmania\/ HIV co-infections WHO Fact Sheet (2000)."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(01)90223-8"},{"key":"e_1_2_1_5_1","unstructured":"\u2022An excellent description of the risk factors and epidemiology of leishmaniasis worldwide."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2004.03.004"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.2.298"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"KHALIL EA, EL-HASSAN IM, EL-HASSAN AM: Post-kala-azar dermal leishmaniasis","volume":"3","author":"ZULSTRA EE","year":"2003","unstructured":"ZULSTRA EE, MUSA AM, KHALIL EA, EL-HASSAN IM, EL-HASSAN AM: Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. (2003) 3:87\u201398.","journal-title":"Lancet Infect. Dis."},{"key":"e_1_2_1_9_1","unstructured":"\u2022\u2022Very good and detailed description of allfacets of PKDL leishmaniasis."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1997.11813179"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6421.895"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6636.1557"},{"key":"e_1_2_1_13_1","first-page":"1","article-title":"Report of a WHO Expert Committee","volume":"793","author":"Control of the leishmaniases","year":"1990","unstructured":"Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser. (1990) 793:1\u2013158.","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"e_1_2_1_14_1","first-page":"1","article-title":"Report of a WHO Expert Committee","volume":"701","author":"The leishmaniases","year":"1984","unstructured":"The leishmaniases. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser. (1984) 701:1\u2013140.","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"e_1_2_1_15_1","first-page":"166","article-title":"Epidemiological, clinical & pharmacological study of antimonyresistant visceral leishmaniasis in Bihar, India","volume":"120","author":"THAKUR CP","year":"2004","unstructured":"THAKUR CP, NARAYAN S, RANJAN A: Epidemiological, clinical & pharmacological study of antimonyresistant visceral leishmaniasis in Bihar, India. Indian J. Med. Res. (2004) 120:166\u2013172.","journal-title":"Indian J. Med. Res."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/318121"},{"key":"e_1_2_1_17_1","unstructured":"\u2022The first description of widespread antimony failure in India."},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/516526"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00778.x"},{"key":"e_1_2_1_20_1","unstructured":"\u2022\u2022A comprehensive description of drugresistance in VL."},{"key":"e_1_2_1_21_1","first-page":"1063","article-title":"Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B","volume":"13","author":"LAGUNA F","year":"1999","unstructured":"LAGUNA F, LOPEZ-VELEZ R, PULIDO F et al: Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS (1999) 13:1063\u20131069.","journal-title":"Spanish HIV-Leishmania Study Group. AIDS"},{"key":"e_1_2_1_22_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2210-2-11","article-title":"In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate","volume":"2","author":"CARRIO J","year":"2002","unstructured":"CARRIO J, PORTUS M: In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol (2002) 2:11.","journal-title":"BMC Pharmacol"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6924.307"},{"key":"e_1_2_1_24_1","first-page":"314","article-title":"Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial","volume":"39","author":"JHA SN","year":"1991","unstructured":"JHA SN, SINGH NK, JHA TK: Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. Assoc. Physicians India (1991) 39:314\u2013316.","journal-title":"Assoc. Physicians India"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(84)90289-X"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(83)90058-5"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1998.11813274"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90268-T"},{"key":"e_1_2_1_29_1","unstructured":"Minutes of the meeting of the Expert Committee for the treatment of Kala-azar in India. (2000)."},{"key":"e_1_2_1_30_1","first-page":"5","article-title":"[Childhood Mediterranean visceral leishmaniasis]","volume":"11","author":"CASCIO A","year":"2003","unstructured":"CASCIO A, COLOMBA C: [Childhood Mediterranean visceral leishmaniasis]. Infez. Med. (2003) 11:5\u201310.","journal-title":"Infez. Med."},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(96)91343-2"},{"key":"e_1_2_1_32_1","first-page":"75","article-title":"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial","volume":"87","author":"DAVIDSON RN","year":"1994","unstructured":"DAVIDSON RN, DI MARTINO L, GRADONI L et al: Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q. I Med. (1994) 87:75\u201381.","journal-title":"Q. I Med."},{"key":"e_1_2_1_33_1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study","volume":"52","author":"LAGUNA F","year":"2003","unstructured":"LAGUNA F, VIDELA S, JIMENEZ-MEJIAS ME et al: Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. Antimicrob. Chemother. (2003) 52:464\u2013468.","journal-title":"Antimicrob. Chemother."},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2003.09.012"},{"key":"e_1_2_1_35_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1365-3156.2000.00555.x","article-title":"A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan","volume":"5","author":"VEEKEN H","year":"2000","unstructured":"VEEKEN H, RITMEIJER K, SEAMAN J, DAVIDSON R: A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop. Med. mt. Health (2000) 5:312\u2013317.","journal-title":"Trop. Med. mt. Health"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(01)90110-5"},{"key":"e_1_2_1_37_1","first-page":"388","article-title":"FLAHERTY D, HEUVELMANS H et al: Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya","volume":"79","author":"MOORE E O&apos","year":"2001","unstructured":"MOORE E, O&apos;FLAHERTY D, HEUVELMANS H et al: Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. (2001) 79:388\u2013393.","journal-title":"Bull. World Health Organ."},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(03)90167-2"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(03)80043-3"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1998.59.139"},{"key":"e_1_2_1_41_1","first-page":"144","article-title":"Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis","volume":"91","author":"THAKUR CP","year":"1990","unstructured":"THAKUR CP, KUMAR K: Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian J. Med. Eec. (1990) 91:144\u2013148.","journal-title":"Indian J. Med. Eec."},{"key":"e_1_2_1_42_1","first-page":"609","article-title":"A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis","volume":"49","author":"DAS VN","year":"2001","unstructured":"DAS VN, RANJAN A, SINHA AN et al: A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J. Assoc. Physicians India (2001) 49:609\u2013613.","journal-title":"J. Assoc. Physicians India"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90406-5"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1998.11813313"},{"key":"e_1_2_1_45_1","doi-asserted-by":"crossref","unstructured":"ADLER-MOORE J PROFFITT RT: AmBisome: liposomal formulation structure mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. (2002) 49\\(Suppl. 0:21\u201330.","DOI":"10.1093\/jac\/49.suppl_1.21"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(96)90271-0"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2002.66.143"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7310.419"},{"key":"e_1_2_1_49_1","unstructured":"\u2022This paper describes the efficacy of a single dose liposomal amphotericin B in VL."},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1086\/377542"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.1.188"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.6.938"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.09.011"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1086\/515085"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.3.711"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.6.981"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(90)90263-E"},{"key":"e_1_2_1_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.3.715"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(95)90503-0"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7139.1200"},{"key":"e_1_2_1_61_1","unstructured":"\u2022A description of the efficacy of paromomycin in VL."},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.6.1041"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04367-0"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1086\/318122"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912093412403"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021556"},{"key":"e_1_2_1_67_1","unstructured":"\u2022\u2022This paper describes the results of thePivotal Phase III miltefosine trial which led to the registration of the drug."},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1086\/380638"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.6.1034"},{"key":"e_1_2_1_70_1","unstructured":"\u2022The first description of the activity of sitamaquine in human VL."},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2001.65.685"},{"key":"e_1_2_1_72_1","unstructured":"JHA T SUNDAR S THAKUR C FELTON J SABIN A HORTON J: A Phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis In India. Amer I Trop. Med. Hyg. In press."},{"key":"e_1_2_1_73_1","unstructured":"WASSUNA M FELTON J SABIN A HORTON J: A Phase II dose-rising study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. I Trop. Med. Hyg. In press."},{"key":"e_1_2_1_74_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jac\/dkh084","article-title":"Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","volume":"53","author":"LOPEZ-VELEZ R","year":"2004","unstructured":"LOPEZ-VELEZ R, VIDELA S, MARQUEZ M et al: Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. Antimicrob. Chemother. (2004) 53:540\u2013543.","journal-title":"Antimicrob. Chemother."},{"key":"e_1_2_1_75_1","unstructured":"\u2022One of the few papers describing the role of secondary prophylaxis in HIV\/VL coinfection."},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012220-00020"},{"key":"e_1_2_1_77_1","doi-asserted-by":"crossref","unstructured":"LAGUNA F: Treatment of leishmaniasis in HIV-positive patients. Ann. Trop. Med. Parasitol (2003) 97\\(Suppl. 1):135\u2013142.","DOI":"10.1179\/000349803225002606"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1198-743x.2001.00270.x"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100960100457"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(00)90277-3"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1998.11813337"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2.2.279"},{"key":"e_1_2_1_83_1","unstructured":"\u2022\u2022An excellent review of the treatment of VL."},{"key":"e_1_2_2_2_1","unstructured":"hdps:\/\/www.medeor-ordecorgipdf\/ medikamente.pdf Action Medeor e.V. medical order form."},{"key":"e_1_2_2_3_1","unstructured":"http:\/\/w3.whosea.org\/EN\/Section316\/ Section503\/Section1861_9726.htm World Health Organization press release."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.6.16.2821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:22:48Z","timestamp":1769721768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.6.16.2821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,30]]},"references-count":83,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1517\/14656566.6.16.2821"],"URL":"https:\/\/doi.org\/10.1517\/14656566.6.16.2821","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,30]]}}}